As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Authors

Christopher J. Logothetis, MD

Chairman/Professor, Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas

Disclosures

Disclosure: Christopher J. Logothetis, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bristol-Myers Squibb Company; Amgen Inc.; Novartis Pharmaceuticals Corporation; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Dr Logothetis does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Logothetis does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Tomasz M. Beer, MD

Professor of Medicine, Staff Physician, Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon

Disclosures

Disclosure: Tomasz M. Beer, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Centocor, Inc.; Ortho Biotech Products, L.P.; Dendreon Corp.; GTx, Inc.
Received grants for clinical research from: Bristol-Myers Squibb Company; Cell Therapeutics, Inc.; Cougar Biotechnology, Inc.; Dendreon Corp.; ImClone Systems Incorporated; Medivation, Inc.; Novartis Pharmaceuticals Corporation; OncoGenex Pharmaceuticals Inc.
Provided expert testimony for: Novartis Pharmaceuticals Corporation

Dr Beer does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Beer does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Johann S. de Bono, MD, PhD

Professor of Experimental Cancer Medicine, University of London, Institute of Cancer Research; Honorary Consultant, Royal Marsden NHS Trust, Sutton, Surrey, UK

Disclosures

Disclosure: Johann S. de Bono, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Cougar Biotechnology, Inc.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; AstraZeneca Pharmaceuticals LP; Medivation, Inc.; Astellas Pharma, Inc.
Served as a speaker or a member of a speakers bureau for: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; sanofi-aventis
Received grants for clinical research from: Pfizer Inc Employed by a commercial interest: Institute of Cancer Research

Dr de Bono does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr de Bono does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Fred Saad, MD

Professor and Chair of Urology, University of Montreal; Chief, Division of Urology, University of Montreal Hospital Center, Montreal, Canada

Disclosures

Disclosure: Fred Saad, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica Products, L.P; sanofi-aventis
Served as a speaker or a member of a speakers bureau for: Amgen Inc.; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica Products, L.P; sanofi-aventis
Received grants for clinical research from: Amgen Inc.; Cougar Biotechnology, Inc.; Medivation, Inc.; Bristol-Myers Squibb Company

Dr Saad does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Saad does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editors

Emir Hadzic, PhD

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Emir Hadzic, PhD, has disclosed no relevant financial relationships.

Ron Schaumburg

Clinical editor, Medscape, LLC

Disclosures

Disclosure: Ron Schaumburg has disclosed no relevant financial relationships.

CME Reviewer

Nafeez Zawahir, MD

CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

CME

Metastatic Castration-Resistant Prostate Cancer: New Targets, New Therapeutic Approaches

Authors: Christopher J. Logothetis, MD; Tomasz M. Beer, MD; Johann Sebastian de Bono, MB, ChB, MSc, PhD; Fred Saad, MD
CME Released: 3/28/2012
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 3/28/2013

Start Activity

Target Audience and Goal Statement

This activity is intended for oncologists, urologists, and other healthcare professionals involved in the management of men with metastatic castration-resistant prostate cancer (mCRPC).

The goal of this activity is to review the current paradigm of mCRPC management including data on the safety, efficacy, and potential benefit of molecularly targeted therapies, and learn about the necessary tools for considering how new targeted therapy approaches might be effectively incorporated into the future treatment paradigm for patients with mCRPC.

Upon completion of this activity, participants will be able to:

Recognize the benefits and limitations of current therapies for men with CRPC
Outline the role of the Src signaling pathway in the development and progression of CRPC
Evaluate clinical trial data on molecularly targeted agents in the management of patients with mCRPC
Describe how to target bone development and function to delay or avoid bone metastasis (Src, RANKL, FGF, Met)
Discuss challenges of integrating new therapies with distinct mechanisms of action (immunotherapy, bone-targeting, chemotherapy, molecularly targeted agents) to maximize outcomes

Disclosures

Authors

Christopher J. Logothetis, MD

Chairman/Professor, Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas

Disclosures

Disclosure: Christopher J. Logothetis, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Bristol-Myers Squibb Company; Amgen Inc.; Novartis Pharmaceuticals Corporation; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Dr Logothetis does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Logothetis does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Tomasz M. Beer, MD

Professor of Medicine, Staff Physician, Hematology and Medical Oncology, Oregon Health and Science University, Portland, Oregon

Disclosures

Disclosure: Tomasz M. Beer, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Centocor, Inc.; Ortho Biotech Products, L.P.; Dendreon Corp.; GTx, Inc.
Received grants for clinical research from: Bristol-Myers Squibb Company; Cell Therapeutics, Inc.; Cougar Biotechnology, Inc.; Dendreon Corp.; ImClone Systems Incorporated; Medivation, Inc.; Novartis Pharmaceuticals Corporation; OncoGenex Pharmaceuticals Inc.
Provided expert testimony for: Novartis Pharmaceuticals Corporation

Dr Beer does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Beer does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Johann S. de Bono, MD, PhD

Professor of Experimental Cancer Medicine, University of London, Institute of Cancer Research; Honorary Consultant, Royal Marsden NHS Trust, Sutton, Surrey, UK

Disclosures

Disclosure: Johann S. de Bono, MD, PhD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Cougar Biotechnology, Inc.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; AstraZeneca Pharmaceuticals LP; Medivation, Inc.; Astellas Pharma, Inc.
Served as a speaker or a member of a speakers bureau for: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; sanofi-aventis
Received grants for clinical research from: Pfizer Inc Employed by a commercial interest: Institute of Cancer Research

Dr de Bono does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr de Bono does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Fred Saad, MD

Professor and Chair of Urology, University of Montreal; Chief, Division of Urology, University of Montreal Hospital Center, Montreal, Canada

Disclosures

Disclosure: Fred Saad, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica Products, L.P; sanofi-aventis
Served as a speaker or a member of a speakers bureau for: Amgen Inc.; Novartis Pharmaceuticals Corporation; Janssen Pharmaceutica Products, L.P; sanofi-aventis
Received grants for clinical research from: Amgen Inc.; Cougar Biotechnology, Inc.; Medivation, Inc.; Bristol-Myers Squibb Company

Dr Saad does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Saad does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editors

Emir Hadzic, PhD

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Emir Hadzic, PhD, has disclosed no relevant financial relationships.

Ron Schaumburg

Clinical editor, Medscape, LLC

Disclosures

Disclosure: Ron Schaumburg has disclosed no relevant financial relationships.

CME Reviewer

Nafeez Zawahir, MD

CME Clinical Director, Medscape, LLC

Disclosures

Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Accreditation Statements

For Physicians

Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME

Metastatic Castration-Resistant Prostate Cancer: New Targets, New Therapeutic Approaches

Authors: Christopher J. Logothetis, MD; Tomasz M. Beer, MD; Johann Sebastian de Bono, MB, ChB, MSc, PhD; Fred Saad, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME Released: 3/28/2012

Valid for credit through: 3/28/2013

processing....

Abbreviations

AA = abiraterone acetate
ABI = androgen biosynthesis inhibitor
ADT = androgen deprivation therapy
AE = adverse event
AI = androgen-independent
AIPC = androgen-independent prostate cancer
ALSYMPCA = ALpharadin in SYMptomatic Prostate CAncer
AR = androgen receptor
ASPC = androgen-sensitive prostate cancer
BAP = bone alkaline phosphatase
BFR = bone formation rate
CML = chronic myelogenous leukemia
CBZP = cabazitaxel
CRPC = castration-resistant prostate cancer
CT = computed tomography
CTC = circulating tumor cell
CTL = control
DHT = dihydrotestosterone
DLT = dose-limiting toxicity
DMSO = dimethyl sulfoxide
ECOG = Eastern Cooperative Oncology Group
EQ-5D = EuroQoL 5 Dimensions
FACT-P = Functional Assessment of Cancer Therapy - Prostate
FGF = fibroblast growth factor
GM-CSF = granulocyte-macrophage colony-stimulating factor
HGF = hepatocyte growth factor
HIV = human immunodeficiency virus
HR = hazard ratio
IDMC = Independent Data Monitoring Committee
IL = interleukin
IMPACT = Immunotherapy for Prostate Adenocarcinoma Treatment trial
ITT = intent to treat
LFT = liver function test
mCRPC = metastatic castration-resistant prostate cancer
MP = mitoxantrone
MCSF = macrophage colony stimulating factor
NTX = collagen type 1 telopeptide
NYR = not yet reached
OS = overall survival
PCa = prostate cancer
PCCTWG = Prostate Cancer Clinical Trials Working Group
PDGFR = platelet-derived receptor growth factor
PK = pharmacokinetics
PFS = progression-free survival
PR= partial response
PSA = prostate-specific antigen
PYD = pyridinoline
QoL = quality of life
RANKL = Undoreceptor activator of nuclear factor kappa-ß ligand
RECIST = Response Evaluation Criteria in Solid Tumors
REDUCE = Reduction by Dutasteride of Prostate Cancer Events study
rPFS = radiologic progression-free survival
RTK = receptor tyrosine kinase family
SCPC = small cell prostate carcinoma
sCTX = serum C-telopeptide cross-links of type 1 collagen
SD = standard deviation
SFK = Src family kinase
SRE = skeletal-related events
STAMPEDE = Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy trial
TRAP = tartrate-resistant alkaline phosphatase
TROPIC = XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer
TTPP = time to PSA progression
uNTX = urinary N-telopeptide cross-links of of type 1 collagen
uPA = urokinase plasminogen activator
VEGFR = vascular endothelial growth factor receptor
XRT = radiotherapy
ZOL = zoledronic acid

« Return to: Metastatic Castration-Resistant Prostate Cancer: New Targets, New Therapeutic Approaches

CME Information Download Slides

Print
Like Tweet

References

Faculty and Disclosures

Authors

Christopher J. Logothetis, MD

Tomasz M. Beer, MD

Johann S. de Bono, MD, PhD

Fred Saad, MD

Editors

Emir Hadzic, PhD

Ron Schaumburg

CME Reviewer

Nafeez Zawahir, MD

CME

Metastatic Castration-Resistant Prostate Cancer: New Targets, New Therapeutic Approaches

Target Audience and Goal Statement

Disclosures

Authors

Christopher J. Logothetis, MD

Tomasz M. Beer, MD

Johann S. de Bono, MD, PhD

Fred Saad, MD

Editors

Emir Hadzic, PhD

Ron Schaumburg

CME Reviewer

Nafeez Zawahir, MD

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Metastatic Castration-Resistant Prostate Cancer: New Targets, New Therapeutic Approaches

Abbreviations